<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR225">
 <label>225.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Folegatti</surname>
    <given-names>PM</given-names>
   </name>
   <name>
    <surname>Bittaye</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Flaxman</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Lopez</surname>
    <given-names>FR</given-names>
   </name>
   <name>
    <surname>Bellamy</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Kupke</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Mair</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Makinson</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Sheridan</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Rohde</surname>
    <given-names>C</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</article-title>
  <source>Lancet Infect Dis</source>
  <year>2020</year>
  <volume>20</volume>
  <issue>7</issue>
  <fpage>816</fpage>
  <lpage>826</lpage>
  <?supplied-pmid 32325038?>
  <pub-id pub-id-type="pmid">32325038</pub-id>
 </element-citation>
</ref>
